Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 20.40% is in line with its 5-year average of 19.25%, near the high end of its 5-year range (-205.62%–30.48%).
61.00% above its 12-month average of 12.67%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -5.75%.
EBITDA MARGIN
20.40%
EBITDA MARGIN AVG TTM
12.67%
EBITDA MARGIN AVG 3Y
17.34%
EBITDA MARGIN AVG 5Y
19.25%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+61.00%
CURRENT VS 3Y AVG
+17.67%
CURRENT VS 5Y AVG
+6.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$49.50M
EBITDA Margin
-203.44%
TTM Avg
-129.78%
3Y Avg
-288.25%
5Y Avg
-438.27%
Market Cap
$49.96M
EBITDA Margin
-10794.00%
TTM Avg
-9994.66%
3Y Avg
-8986.60%
5Y Avg
-8678.68%
Market Cap
$50.25M
EBITDA Margin
-9115.35%
TTM Avg
-8798.34%
3Y Avg
-6751.54%
5Y Avg
-5839.94%
Market Cap
$50.51M
EBITDA Margin
-108.45%
TTM Avg
-10676.44%
3Y Avg
-10454.97%
5Y Avg
-429870.64%
Market Cap
$51.58M
EBITDA Margin
-61570.00%
TTM Avg
-181077.86%
3Y Avg
-90538.93%
5Y Avg
-60359.29%
Market Cap
$46.79M
EBITDA Margin
-0.99%
TTM Avg
4.72%
3Y Avg
-25.09%
5Y Avg
-32.37%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| biote Corp. (BTMD) | $49.40M | 20.40% | 12.67% | 17.34% | 19.25% |
| Celularity Inc. (CELU)vs › | $49.50M | -203.44% | -129.78% | -288.25% | -438.27% |
| Clene Inc. (CLNN)vs › | $49.96M | -10794.00% | -9994.66% | -8986.60% | -8678.68% |
| Envoy Medical, Inc. (COCH)vs › | $50.25M | -9115.35% | -8798.34% | -6751.54% | -5839.94% |
| Apollomics, Inc. (APLM)vs › | $50.51M | -108.45% | -10676.44% | -10454.97% | -429870.64% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $51.58M | -61570.00% | -181077.86% | -90538.93% | -60359.29% |
| BioStem Technologies, Inc. (BSEM)vs › | $46.79M | -0.99% | 4.72% | -25.09% | -32.37% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.95M | -36.23% | -36.23% | -36.23% | -36.23% |
Gross Margin
71.5%
EBITDA Margin
20.4%
Operating Margin
18.5%
Net Margin
3.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -5.75% |
| 2026-03-31 | 9.23% |
| 2025-12-31 | 16.76% |
| 2025-09-30 | 19.22% |
| 2025-06-30 | 23.89% |
| 2025-03-31 | 21.53% |
| 2024-12-31 | 7.84% |
| 2024-09-30 | 25.29% |
| 2024-06-30 | 13.86% |
| 2024-03-31 | 23.88% |
| 2023-12-31 | 12.29% |
| 2023-09-30 | 17.59% |
| 2023-06-30 | 16.65% |
| 2023-03-31 | 18.77% |
| 2022-12-31 | 17.66% |
| 2022-09-30 | 20.00% |
| 2022-06-30 | -205.62% |
| 2022-03-31 | 27.64% |
| 2021-12-31 | 16.89% |
| 2021-09-30 | 26.19% |
| 2021-06-30 | 30.48% |
| 2021-03-31 | 30.33% |
| 2020-12-31 | 32.89% |
